This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Cormorant Asset Management sold 775,000 Arcellx shares in the fourth quarter. The fund's quarter-end position value in Arcellx decreased by $63.63 million, reflecting a complete position sale during the period.